What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 24447.png

LEQVIO® Is a First-in-Class LDL-C-Lowering Therapy1.

LEQVIO®, the First and Only siRNA (Small Interfering RNA) Therapy for LDL-C Reduction, Selectively Targets the Liver.1,2
 

  • Works differently than other LDL-C-lowering treatments as a complements to statins.1,3
  • Prevents the formation of the protein that promotes the degradation of LDL receptors1.
  • Allows for greater uptake of LDL-C into hepatocytes1.
  • LEQVIO® reaches undetectable levels in circulation within 48 hours of administration and
plasma concentration decline within 24 hours of administration1.
  • No clinically meaningful interactions are expected with LEQVIO®.1

How LEQVIO® works

LEQVIO® enhances the liver's ability to effectively clear LDL-C from the bloodstream4

image 6.png
  • LEQVIO® is taken up by hepatocytes and is slowly released into the cytoplasm, where LEQVIO® loads onto the RNA-induced silencing complex (RISC)4
  • LEQVIO® works with RISC to sequentially cleave multiple copies of target protein mRNA, which continuously prevents target protein production4
image 5.png
  • LDL receptors increase on the surface of the hepatocyte, which results in greater hepatic uptake of circulating LDL-C4

LEQVIO® NSS -  UAE

PDF
View

References

  1. LEQVIO®. Core Data Sheet. Novartis Europharma limited.

  2. https://www.novartis.com/news/media-releases/novartis-receives-eu-approv....


  3. Feingold KR, Cholesterol Lowering drugs. Endotext. Published 2000. Updated March 29, 2020. Accessed September 15,2020. https://www.endotext/chapter/cholesterol-lowering-drugs/.


  4. Khvorova A. Oligonucleotide therapeutics -a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEjMp1614154.